Scarica l'app Stockscreener
29.00
4.89%
-1.49
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché VKTX Giù?
Forum
Previsione
Viking Therapeutics Inc Borsa (VKTX) Ultime notizie
Can Viking Therapeutics Inc. maintain its current growth rateFed Meeting & Short-Term Swing Trade Alerts - mfd.ru
Accessible Health Platforms Gain Scale Across $6T Health and Wellness Market - Benzinga
Viking Therapeutics (VKTX) Is Up 16.0% After Fast-Tracking VK2735 Into Phase III Trials – Has The Bull Case Changed? - Yahoo Finance
Viking Therapeutics: Buyers Are Quietly Accumulating On Its Obesity Drugs Launch Potential - Seeking Alpha
We Think Viking Therapeutics (NASDAQ:VKTX) Can Afford To Drive Business Growth - 富途牛牛
Viking Therapeutics Advances VK2735 Toward Phase 3 After FDA Feedback - AD HOC NEWS
What is HC Wainwright's Forecast for VKTX Q4 Earnings? - MarketBeat
Is Viking Therapeutics (VKTX) Pricing Reflecting Recent Drug Development Progress? - simplywall.st
Viking Therapeutics' VK2735 Sees Strong Demand Amid Novo Nordisk Launch - Intellectia AI
VKTX Stock Has Nearly 300% Wall Street Upside — Is Viking’s Oral Obesity Pill The Next Novo Nordisk-Style Breakout? - Stocktwits
Pipeline Momentum Boosts Viking Therapeutics as Phase 3 Timeline Accelerates - AD HOC NEWS
Viking Therapeutics (VKTX) Valuation Check After Q4 2025 Earnings And Obesity Pipeline Progress - Yahoo Finance
Viking Therapeutics stock rating reiterated at Buy by Laidlaw - Investing.com Nigeria
Viking Therapeutics Bets Big on Obesity Breakthroughs - TipRanks
Viking Therapeutics, Inc. (NASDAQ:VKTX) Q4 2025 earnings call transcript - MSN
Viking Therapeutics (NASDAQ:VKTX) Shares Gap UpTime to Buy? - MarketBeat
Viking Therapeutics pushes GLP-1/GIP obesity pill to phase 3 - TechTarget
Viking to push oral GLP-1/GIP drug into phase III obesity trial - BioWorld MedTech
Viking Therapeutics Stock Soars: What's Driving The Momentum? - Benzinga
Stock Movers: Equinix, Crocs, Viking Therapeutics - Bloomberg.com
Viking Therapeutics stock price target lowered to $118 by Raymond James By Investing.com - Investing.com Canada
Viking Therapeutics stock rating reiterated at Buy by Laidlaw By Investing.com - Investing.com South Africa
Viking Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Provides Corporate Update - marketscreener.com
Morgan Stanley Maintains Viking Therapeutics(VKTX.US) With Buy Rating, Cuts Target Price to $99 - 富途牛牛
Viking Therapeutics (VKTX) Shares Rise on Promising Obesity Drug Updates - GuruFocus
Viking Therapeutics, Inc. (NASDAQ:VKTX) Q4 2025 Earnings Call Transcript - Insider Monkey
Viking Therapeutics, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
VKTX Posts Wider-Than-Expected Loss in Q4, Stock Up on Pipeline Updates - Yahoo Finance
Viking Therapeutics stock price target lowered to $118 by Raymond James - Investing.com
Viking Therapeutics rises after Q4 updates (VKTX:NASDAQ) - Seeking Alpha
Viking Therapeutics Advances Oral Obesity Drug Toward Final Clinical Trials - AD HOC NEWS
Morgan Stanley Trims Price Target on Viking Therapeutics to $99 From $102, Keeps Overweight Rating - marketscreener.com
12 Health Care Stocks Moving In Thursday's Pre-Market Session - Benzinga
Viking Therapeutics stock soars on plans for Phase 3 obesity drug trial - Investing.com
Viking Therapeutics stock (VKTX) slips premarket as Phase 3 obesity pill timeline comes into focus - Bez Kabli
Viking Therapeutics, Inc. (VKTX) shares surged 11.7% in pre-market trading after the company announced plans to advance its oral obesity treatment drug to late-stage trials. - Bitget
Viking Therapeutics outlines dual Phase III obesity programs while advancing oral VK2735 and maintenance regimens - MSN
VKTX Stock Rallies After Hours On Optimism Around Company’s Obesity Pipeline - Stocktwits
Viking Therapeutics plans to advance oral obesity drug to late-stage testing - whbl.com
Viking Therapeutics Q4 2025 Earnings Call Highlights - Intellectia AI
Viking Therapeutics (VKTX) Advances Obesity Pipeline Amidst Fina - GuruFocus
Decoding Viking Therapeutics Inc (VKTX): A Strategic SWOT Insigh - GuruFocus
Viking Therapeutics Inc (VKTX) Q4 2025 Earnings Call Highlights: Strategic Advances Amid Rising R&D Costs - GuruFocus
Viking (VKTX) Q4 2025 Earnings Call Transcript - The Globe and Mail
Viking Therapeutics Q4 2025 Earnings Call Transcript - MarketBeat
Viking Therapeutics stock climbs after Q4 report: Details - MSN
Earnings call transcript: Viking Therapeutics Q4 2025 misses EPS forecast By Investing.com - Investing.com Nigeria
Viking Therapeutics reports Q4 EPS ($1.38), consensus (90c) - TipRanks
Viking Therapeutics Q4 Earnings Call Highlights - MarketBeat
Earnings call transcript: Viking Therapeutics Q4 2025 misses EPS forecast - Investing.com
How Viking’s Q4 2025 Earnings and VK2735 Weight-Loss Updates Will Impact Viking Therapeutics (VKTX) Investors - simplywall.st
Viking Therapeutics, Inc. SEC 10-K Report - TradingView
VKTX: Late-stage clinical progress and strong cash reserves position the company for future growth - TradingView
Viking Therapeutics (VKTX) Reports Q4 EPS Miss and Advances Obes - GuruFocus
Viking (VKTX) Advances Obesity Treatment with Key Developments - GuruFocus
Viking Therapeutics Q4 Loss Widens - marketscreener.com
Viking Therapeutics plans to advance oral obesity drug to late-stage trial - marketscreener.com
Earnings Flash (VKTX) Viking Therapeutics, Inc. Reports Q4 Revenue $0K - marketscreener.com
Viking Therapeutics Stock Climbs After Q4 Report: Details - Benzinga
Viking Therapeutics (NASDAQ:VKTX) Announces Earnings Results - MarketBeat
1.12%
0.87%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):